Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25932103 | 0.89 | HDAC11 (0.76) | HDAC11NPC1RAB9AHDAC6 | |
| SCHEMBL21496773 | 0.86 | HDAC11 (0.79) | HDAC11HDAC6 | |
| SCHEMBL25932254 | 0.82 | HDAC11 (0.53) | HDAC11HDAC6 | |
| SCHEMBL21496674 | 0.79 | HDAC11 (0.55) | HDAC11HDAC6 | |
| SCHEMBL21496747 | 0.78 | HDAC11 (0.59) | HDAC11HDAC6 | |
| SCHEMBL21496714 | 0.76 | HDAC11 (0.52) | HDAC11RAB9AHDAC6PRMT5WDR77 | |
| SCHEMBL21496807 | 0.74 | HDAC11 (1.00) | HDAC11HDAC6 | |
| SCHEMBL30038158 | 0.74 | HDAC11 (1.00) | HDAC11HDAC6 | |
| SCHEMBL21500450 | 0.74 | HDAC11 (1.00) | HDAC11HDAC6 | |
| SCHEMBL25932303 | 0.73 | HDAC11 (0.53) | HDAC11NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | HDAC11 4/4885NPC1 1706/4885RAB9A 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.